Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Acceptance, efficacy and preference of Sildenafil in patients on long term auto-intracavernosal therapy: a study with follow-up at one year

Abstract

Purpose: To assess the acceptance, long term efficacy and preference of Sildenafil in impotent patients previously on auto-intracavernosal therapy.

Material and methods: The patients were the 107 men (mean age 58.4 y) on auto-intracavernosal therapy (auto-IC) for more than 6 months (mean duration 32.7 months >12 months in 100) who were consecutively seen within 6 months of the launch of Sildenafil in France. If there was no contra-indications to Sildenafil they were proposed a trial of Sildenafil at home. Following this trial they were given the possibility to change their therapy and were followed for 1 y at 3 months intervals.

Results: Three patients had contra-indications to Sildenafil. Of the remaining 104, 45 (43%) refused the trial, mainly because they were afraid of possible cardiac risks (n=21, including 51% of the psychogenic and mixed patients compared to 8% of the predominantly organic ones). Among the 59 who tried it, Sildenafil gave good results in 46 (78%), including 100% of the predominantly psychogenic and 61.5% of the predominantly organic ones) with minimum effective doses of 25 mg in 7, 50 mg in 18 and 100 mg in 21. It failed in 9 (15%) and gave average results in 4 (penetration with a non fully satisfying erection). There was a clear relationship between the sensitivity to Sildenafil and that to Alprostadil, the vasoactive agent predominantly used for the auto-ICIs. Every 46 patients with good result of Sildenafil elected to continue with this drug, including 3 who used both Sildenafil and auto-ICIs in alternance. Every 4 patients with average results elected to continue with auto-ICI including 1 who also used Sildenafil in alternance. Five of the 50 patients with good or average results were lost to follow-up within 6 months. At the 1 y follow-up visit, 43 of the 45 others were still using Sildenafil, in alternance with auto-ICI in 1. No one reported a decrease in efficacy with time. The 2 patients with average results still in the study were on auto-ICIs.

Conclusion: Sildenafil is highly effective in the impotent men previously treated with auto-ICI and its efficacy is maintained at least for 1 y. When tried and effective it is preferred by most men but almost half of our patients refused trying it.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Krane R, Brock G, Eardley I, Fourcroy J, Giuliano F, Hutter A, Teloken C, Vickers M . Oral non endocrine treatment In: Proceedings of the 1st International Consultation on Erectile Dysfunction, July 1–3, 1999, Paris, Jardin A, Wagner G, Khoury S, Giuliano F, Padma-Nathan H, Rosen R eds. Erectile Dysfunction Health Publication Ltd 2000 pp 243–303.

    Google Scholar 

  2. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH . Clinical safety of oral Sildenafil citrate (VIAGRA™) in the treatment of erectile dysfunction Int J Impot Research 1998; 10: 69–74.

    Article  CAS  Google Scholar 

  3. Hatzichristou D, Apostolidis A, Tzortzis V, Ioannides E, Yannakoyorgos K, Kalinderis A . Sildenafil versus intracavernous injection therapy: Efficacy and preference in patients on intracavernous injection for more than 1 year J Urol 2000; 164: 1197–1200.

    Article  CAS  Google Scholar 

  4. McMahon C, Samali R, Johnson H . Efficacy, safety and patient acceptance of Sildenafil citrate as treatment for erectile dysfunction J Urol 2000; 164: 1192–1196.

    Article  CAS  Google Scholar 

  5. Giuliano F, Montorsi F, Mirone V, Rossi D . Sweeney M for the Sildenafil multicenter study group. Switching from intracavernous prostaglandine E1 injections to oral Sildenafil citrate in patients with erectile dysfunction: results of a multicenter european study J Urol 2000; 164: 708–711.

    Article  CAS  Google Scholar 

  6. Sadovsky R, Miller T, Moskowitz M, Hackett G . Three-year update of Sildenafil citrate (Viagra®) efficacy and safety Int J Clinical Practice 2001; 55: 115–128.

    CAS  Google Scholar 

  7. Shabsigh R, Padma-Nathan H, Gittleman M, Mc Murray J, Kaufman J, Goldstein I . Intracavernous alprostadil alfadex (Edex/Viridal) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra) Urology 2000; 55: 477–480.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J Buvat.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buvat, J., Lemaire, A. & Ratajczyk, J. Acceptance, efficacy and preference of Sildenafil in patients on long term auto-intracavernosal therapy: a study with follow-up at one year. Int J Impot Res 14, 483–486 (2002). https://doi.org/10.1038/sj.ijir.3900913

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3900913

Keywords

This article is cited by

Search

Quick links